159 related articles for article (PubMed ID: 14755012)
21. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial.
Bekes I; Eichler M; Singer S; Friedl TWP; Harbeck N; Rack B; Forstbauer H; Dannecker C; Huober J; Kiechle M; Lato K; Janni W; Fink V
Clin Breast Cancer; 2020 Dec; 20(6):439-447. PubMed ID: 32800493
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
23. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
Chang J; Couture F; Young S; McWatters KL; Lau CY
J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
[TBL] [Abstract][Full Text] [Related]
24. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Hudis C; Fornier M; Riccio L; Lebwohl D; Crown J; Gilewski T; Surbone A; Currie V; Seidman A; Reichman B; Moynahan M; Raptis G; Sklarin N; Theodoulou M; Weiselberg L; Salvaggio R; Panageas KS; Yao TJ; Norton L
J Clin Oncol; 1999 Apr; 17(4):1118. PubMed ID: 10561169
[TBL] [Abstract][Full Text] [Related]
25. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
26. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
[TBL] [Abstract][Full Text] [Related]
27. Breast conservation after induction chemotherapy for locally advanced breast cancer.
Kling KM; Ostrzega N; Schmit P
Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
[TBL] [Abstract][Full Text] [Related]
28. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
29. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
30. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
31. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
32. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
33. Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancer.
Mortimer JE; Waliany S; Dieli-Conwright CM; Patel SK; Hurria A; Chao J; Tiep B; Behrendt CE
Cancer; 2017 May; 123(10):1810-1816. PubMed ID: 28061004
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
35. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy.
Denison U; Baumann J; Peters-Engl C; Samonigg H; Krippl P; Lang A; Obermair A; Wagner H; Sevelda P
Breast Cancer Res Treat; 2003 Jun; 79(3):347-53. PubMed ID: 12846419
[TBL] [Abstract][Full Text] [Related]
36. [Role of taxanes in treatment of breast cancer].
Gorbunova VA; Besova NS
Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
[No Abstract] [Full Text] [Related]
37. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen.
Fukuda M; Yamaguchi S; Ohta T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):77-81. PubMed ID: 10442369
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
40. [Breast cancer: HER2 changes one's cards on the table].
Lopez M
Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]